Hims & Hers Stock Falls After Q1 Revenue and Profit Miss

Key Financial Highlights

Hims & Hers Health reported first-quarter revenue that missed Wall Street expectations and posted a surprise net loss. The telehealth company's stock fell more than 12% in extended trading following the announcement, reflecting investor concern over its current financial performance.

Situational Overview

For the first quarter, revenue was $608.1 million, falling short of the consensus estimate of $616.85 million. The company reported a loss of 40 cents per share, contrasting sharply with analysts' expectations for a profit of 4 cents per share. These results were driven by a strategic shift toward offering branded GLP-1 weight-loss drugs, which incurred significant restructuring and write-down costs.

Economic and Market Impact

Despite the quarterly setback, Hims & Hers raised its full-year revenue forecast to a range of $2.8 billion to $3.0 billion, up from previous guidance. Management cited expectations of strong sales from its partnership with Novo Nordisk and international expansion. However, monthly revenue per average subscriber declined to $80 from $85 a year earlier. The company anticipates returning to profitability in 2027.

Summary

The company's short-term performance reflects the high costs of transitioning its weight-loss business model. Investors are weighing these current losses against an optimistic long-term growth forecast, which is now tied to FDA-approved treatments and partnerships with major pharmaceutical firms.

FAQ

Q: Why did Hims & Hers report a loss in Q1?
A: The loss was primarily due to write-downs on ingredients for compounded drugs, plus one-time legal and merger costs related to its strategic shift to branded GLP-1 medications.

Q: What is the company's revenue forecast for the full year?
A: Hims & Hers raised its annual revenue forecast to a new range of $2.8 billion to $3.0 billion.

Source: Investing.com